C57BL/6JCya-Alkem1/Cya
Common Name:
Alk-KO
Product ID:
S-KO-17058
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Alk-KO
Strain ID
KOCMP-11682-Alk-B6J-VA
Gene Name
Product ID
S-KO-17058
Gene Alias
CD246; Tcrz
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
17
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Alkem1/Cya mice (Catalog S-KO-17058) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000086639
NCBI RefSeq
NM_007439
Target Region
Exon 4
Size of Effective Region
~1.1 kb
Detailed Document
Overview of Gene Research
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase. It plays a crucial role in various biological processes, and its abnormal activation can lead to oncogenesis. Different ALK gene alterations, such as point mutations, deletions, and rearrangements, have been identified across a range of tumour types [2]. These alterations can disrupt normal cellular signalling pathways, making ALK an important target for cancer research [2].
ALK rearrangements are oncogenic drivers in several malignancies, most notably in 3-7% of advanced non-small cell lung cancer (NSCLC) [3,5]. In NSCLC, the EML4-ALK fusion is the most prevalent, with different EML4-ALK variants showing differential responses to ALK tyrosine kinase inhibitors (TKIs) [2,7]. In neuroblastoma, ALK is an oncogenic driver, and ALK inhibitors can increase ALK expression, sensitizing cells to ALK.CAR-T cells [1]. Resistance to ALK inhibitors, both on-target and off-target, is a significant issue. For example, different ALK inhibitors are associated with distinct spectra of ALK resistance mutations, and sequential use of inhibitors can lead to the emergence of compound ALK mutations that confer resistance to drugs like lorlatinib [4,6].
In conclusion, ALK is a key molecule in cancer biology, especially in NSCLC and neuroblastoma. Research on ALK, including studies using genetic models (although not specifically KO/CKO mouse models in the provided references), has led to the development of ALK-targeted drugs. Understanding ALK's role in tumour biology and resistance mechanisms to its inhibitors is crucial for optimizing therapeutic strategies for ALK-positive diseases.
References:
1. Bergaggio, Elisa, Tai, Wei-Tien, Aroldi, Andrea, Dotti, Gianpietro, Chiarle, Roberto. 2023. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. In Cancer cell, 41, 2100-2116.e10. doi:10.1016/j.ccell.2023.11.004. https://pubmed.ncbi.nlm.nih.gov/38039964/
2. Hallberg, B, Palmer, R H. . The role of the ALK receptor in cancer biology. In Annals of oncology : official journal of the European Society for Medical Oncology, 27 Suppl 3, iii4-iii15. doi:10.1093/annonc/mdw301. https://pubmed.ncbi.nlm.nih.gov/27573755/
3. Poei, Darin, Ali, Sana, Ye, Shirley, Hsu, Robert. 2024. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies. In Cancer drug resistance (Alhambra, Calif.), 7, 20. doi:10.20517/cdr.2024.25. https://pubmed.ncbi.nlm.nih.gov/38835344/
4. Gainor, Justin F, Dardaei, Leila, Yoda, Satoshi, Engelman, Jeffrey A, Shaw, Alice T. 2016. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. In Cancer discovery, 6, 1118-1133. doi:. https://pubmed.ncbi.nlm.nih.gov/27432227/
5. Desai, Aakash, Lovly, Christine M. 2023. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. In Translational lung cancer research, 12, 615-628. doi:10.21037/tlcr-22-708. https://pubmed.ncbi.nlm.nih.gov/37057106/
6. Yoda, Satoshi, Lin, Jessica J, Lawrence, Michael S, Hata, Aaron N, Shaw, Alice T. 2018. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. In Cancer discovery, 8, 714-729. doi:10.1158/2159-8290.CD-17-1256. https://pubmed.ncbi.nlm.nih.gov/29650534/
7. Zhang, Shannon S, Nagasaka, Misako, Zhu, Viola W, Ou, Sai-Hong Ignatius. 2021. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. In Lung cancer (Amsterdam, Netherlands), 158, 126-136. doi:10.1016/j.lungcan.2021.06.012. https://pubmed.ncbi.nlm.nih.gov/34175504/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen